3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
8
Carboplatin
6
Cyclophosphamide
5
veliparib
4
olaparib
4
Magnetic Resonance Spectroscopy
4
liposomal doxorubicin
3
Taxes
3
Paclitaxel
3
Gene Expression Profiling
3
Gemcitabine
3
palbociclib
2
niraparib
2
fludarabine
2
durvalumab
2
Temozolomide
2
Specimen Handling
2
Psychiatric Rehabilitation
2
Polymerase Chain Reaction
2
Oxaliplatin
2
Nivolumab
2
Leucovorin
2
Interleukin-2
2
Fulvestrant
2
Fluorouracil
2
Early Intervention, Educational
2
Drug Therapy
2
Doxorubicin
2
Biopsy
2
130-nm albumin-bound paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
tinostamustine
×
Breast
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts